ArticleJournal of clinical medicine2021
Diaphragmatic Point-of-Care Ultrasound in COVID-19 Patients in the Emergency Department-A Proof-of-Concept Study.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05805579 (Prognostic Value of Transthoracic Diaphragmatic Echography in COVID-19 Pneumonia Patients With Acute Respiratory Failure), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognostic Value of Transthoracic Diaphragmatic Echography in COVID-19 Pneumonia Patients With Acute Respiratory Failure
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Systematic Review of Commercially Available Clinical CMUT-Based Systems for Use in Medical Ultrasound Imaging: Products, Applications, and Performance.Sensors (Basel, Switzerland) · 2025Pooled it
- Combined diaphragm and lung ultrasound profiling in healthy full-term neonates: a study of early postnatal function.European journal of pediatrics · 2026Observational
- Diaphragm Contraction Pressure Index: A New Forecasting Indicator for Weaning from Mechanical Ventilation.International journal of general medicine · 2025Article
- Diaphragm Ultrasound in Different Clinical Scenarios: A Review with a Focus on Older Patients.Geriatrics (Basel, Switzerland) · 2024Review
- Point-of-care ultrasound use in COVID-19: a narrative review.Annals of translational medicine · 2024Review
- Feasibility of Self-Performed Lung Ultrasound with Remote Teleguidance for Monitoring at Home COVID-19 Patients.Biomedicines · 2022Article
- Diaphragm ultrasound evaluation during weaning from mechanical ventilation in COVID-19 patients: a pragmatic, cross-section, multicenter study.Respiratory research · 2022Observational
- Prognostic Value of Diaphragmatic Ultrasound in Patients Admitted for COVID-19 Pneumonia.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung Ultrasound Evaluation (LUS) is usefully applied in the Emergency Department (ED) to patients with suspected or confirmed COVID-19. Diaphragmatic Ultrasound (DUS) may provide additional insight into ventilatory function. This proof-of-concept study aimed to evaluate the feasibility of LUS and DUS in a third level ED during the COVID-19 pandemic.
methodsAdult patients presenting with COVID-19 symptoms were eligible. After the physical examination, both LUS and DUS (i.e., diaphragmatic motion and thickness) were performed. All patients were followed after 30 days to determine their need for ventilation, admission, and/or a new ED evaluation after discharge. The diagnostic accuracies of diaphragm measurements in assessing the risk of the 30-day outcome were calculated as well as the measurements' usefulness. Bland-Altman plots were used for comparing bedside and off-line diaphragm measurements.
results118 patients were enrolled. Median thickness and motion were 1.7 mm (iqr 0.4) and 1.8 cm (iqr 0.7), respectively, with a mean difference of 0.009 mm (95% CI -0.037-0.056 mm) and -0.051 cm (95% CI -0.108-0.006 cm), respectively. The 30-day outcome was associated with an increase in thickness (OR 5.84, 95% CI 0.96-35.4), and a lower motion (OR 0.49, 95% CI 0.2-1.21).
conclusionDUS seemed to be feasible and reliable in the ED in a population of patients presenting with symptoms related to COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.